📣 VC round data is live. Check it out!

Niagen Bioscience Valuation Multiples

Discover revenue and EBITDA valuation multiples for Niagen Bioscience and similar public comparables like Medy-Tox, Zhejiang Shouxiangu, Grape King Bio, Tempo Scan Pacific and more.

Niagen Bioscience Overview

About Niagen Bioscience

Niagen Bioscience Inc is the leader in NAD+ (nicotinamide adenine dinucleotide) science and healthy-aging research. It is dedicated to advancing healthspan through precision science and innovative NAD+-boosting solutions. It is is clinically proven to increase NAD+ levels efficiently and effectively, and is the key ingredient powering our suite of Niagen brands.


Founded

2000

HQ

United States

Employees

104

Financials (LTM)

Revenue: $135M
EBITDA: $24M

EV

$330M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Niagen Bioscience Financials

Niagen Bioscience reported last 12-month revenue of $135M and EBITDA of $24M.

In the same LTM period, Niagen Bioscience generated $87M in gross profit, $24M in EBITDA, and $19M in net income.

Revenue (LTM)


Niagen Bioscience P&L

In the most recent fiscal year, Niagen Bioscience reported revenue of $129M and EBITDA of $16M.

Niagen Bioscience is profitable as of last fiscal year, with gross margin of 64%, EBITDA margin of 12%, and net margin of 13%.

See analyst estimates for Niagen Bioscience
LTMLast FY202320242025202620272028
Revenue$135M$129M$84M$100M$129M
Gross Profit$87M$83M$51M$62M$83M
Gross Margin64%64%61%62%64%
EBITDA$24M$16M($4M)$9M$16M
EBITDA Margin17%12%(5%)9%12%
EBIT Margin12%11%(7%)8%11%
Net Profit$19M$17M($5M)$9M$17M
Net Margin14%13%(6%)9%13%

Financial data powered by Morningstar, Inc.

Niagen Bioscience Stock Performance

Niagen Bioscience has current market cap of $392M, and enterprise value of $330M.

Market Cap Evolution


Niagen Bioscience's stock price is $4.92.

Niagen Bioscience share price increased by 4.3% in the last 30 days, and decreased by 54.5% in the last year.

Niagen Bioscience has an EPS (earnings per share) of $0.22.

See more trading valuation data for Niagen Bioscience
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$330M$392M1.5%4.3%-2.5%-54.5%$0.22

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Niagen Bioscience Valuation Multiples

Niagen Bioscience trades at 2.4x EV/Revenue multiple, and 14.1x EV/EBITDA.

See NTM and 2027E valuation multiples for Niagen Bioscience

EV / Revenue (LTM)


Niagen Bioscience Financial Valuation Multiples

As of May 5, 2026, Niagen Bioscience has market cap of $392M and EV of $330M.

Niagen Bioscience has a P/E ratio of 20.5x.

LTMLast FY202320242025202620272028
EV/Revenue2.4x2.6x4.0x3.3x2.6x
EV/EBITDA14.1x21.0x(84.9x)35.9x21.0x
EV/EBIT20.2x23.1x(59.0x)42.8x23.1x
EV/Gross Profit3.8x4.0x6.5x5.4x4.0x
P/E20.5x22.6x(79.4x)45.9x22.6x
EV/FCF16.9x25.0x47.4x27.7x25.0x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Niagen Bioscience Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Niagen Bioscience Margins & Growth Rates

In the most recent fiscal year, Niagen Bioscience reported gross margin of 64%, EBITDA margin of 12%, and net margin of 13%.

See estimated margins and future growth rates for Niagen Bioscience

Niagen Bioscience Margins

Last FY20242025202720282029
Gross Margin64%62%64%
EBITDA Margin12%9%12%
EBIT Margin11%8%11%
Net Margin13%9%13%
FCF Margin10%12%10%

Niagen Bioscience Growth Rates

23/2424/2526/2727/2828/29
Revenue Growth19%30%
Gross Profit Growth21%35%
EBITDA Growth(337%)71%
EBIT Growth(238%)85%
Net Profit Growth(273%)103%
FCF Growth71%11%

Data powered by FactSet, Inc. and Morningstar, Inc.

Niagen Bioscience Operational KPIs

Niagen Bioscience's revenue per employee in the last FY averaged $1.2M, while opex per employee averaged $0.7M for the same period.

Access forward-looking KPIs for Niagen Bioscience
LTMLast FY202320242025202620272028
Rule of 4032%————
Bessemer Rule of X54%————
Revenue per Employee—$1.2M———
Opex per Employee—$0.7M———
S&M Expenses to Revenue28%27%32%30%27%
G&A Expenses to Revenue21%21%30%18%21%
R&D Expenses to Revenue5%5%6%6%5%
Opex to Revenue—53%67%54%53%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Niagen Bioscience Competitors

Niagen Bioscience competitors include Medy-Tox, Zhejiang Shouxiangu, Grape King Bio, Tempo Scan Pacific, Vita Life Sciences, Scitop Bio-tech, Venture Life Group, FitLife Brands, Enzymatica and Hofseth BioCare.

Most Niagen Bioscience public comparables operate across Nutraceuticals & Cosmeceuticals.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Medy-Tox2.9x2.9x26.4x25.0x
Zhejiang Shouxiangu4.6x4.6x13.5x—
Grape King Bio1.2x1.2x4.4x—
Tempo Scan Pacific0.5x—3.5x—
Vita Life Sciences1.1x—6.7x—
Scitop Bio-tech10.9x—28.8x—
Venture Life Group1.3x1.0x8.2x6.1x
FitLife Brands1.6x1.5x12.6x9.1x

This data is available for Pro users. Sign up to see all Niagen Bioscience competitors and their valuation data.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Niagen Bioscience

When was Niagen Bioscience founded?Niagen Bioscience was founded in 2000.
Where is Niagen Bioscience headquartered?Niagen Bioscience is headquartered in United States.
How many employees does Niagen Bioscience have?As of today, Niagen Bioscience has over 104 employees.
Who is the CEO of Niagen Bioscience?Niagen Bioscience's CEO is Robert N. Fried.
Is Niagen Bioscience publicly listed?Yes, Niagen Bioscience is a public company listed on Nasdaq.
What is the stock symbol of Niagen Bioscience?Niagen Bioscience trades under NAGE ticker.
When did Niagen Bioscience go public?Niagen Bioscience went public in 2008.
Who are competitors of Niagen Bioscience?Niagen Bioscience main competitors include Medy-Tox, Zhejiang Shouxiangu, Grape King Bio, Tempo Scan Pacific, Vita Life Sciences, Scitop Bio-tech, Venture Life Group, FitLife Brands, Enzymatica, Hofseth BioCare.
What is the current market cap of Niagen Bioscience?Niagen Bioscience's current market cap is $392M.
What is the current revenue of Niagen Bioscience?Niagen Bioscience's last 12 months revenue is $135M.
What is the current revenue growth of Niagen Bioscience?Niagen Bioscience revenue growth (NTM/LTM) is 15%.
What is the current EV/Revenue multiple of Niagen Bioscience?Current revenue multiple of Niagen Bioscience is 2.4x.
Is Niagen Bioscience profitable?Yes, Niagen Bioscience is EBITDA-positive (as of the last 12 months).
What is the current EBITDA of Niagen Bioscience?Niagen Bioscience's last 12 months EBITDA is $24M.
What is Niagen Bioscience's EBITDA margin?Niagen Bioscience's last 12 months EBITDA margin is 17%.
What is the current EV/EBITDA multiple of Niagen Bioscience?Current EBITDA multiple of Niagen Bioscience is 14.1x.
What is the current FCF of Niagen Bioscience?Niagen Bioscience's last 12 months FCF is $20M.
What is Niagen Bioscience's FCF margin?Niagen Bioscience's last 12 months FCF margin is 15%.
What is the current EV/FCF multiple of Niagen Bioscience?Current FCF multiple of Niagen Bioscience is 16.9x.
How many companies Niagen Bioscience has acquired to date?Niagen Bioscience hasn't acquired any companies yet (or none have been disclosed publicly).
In how many companies Niagen Bioscience has invested to date?Niagen Bioscience hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Niagen Bioscience

Lists including Niagen Bioscience

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial